Evotec OAI to Apply New Rational Drug Design Platform to High Priority Research Programme from ActivBiotics

30-Jul-2004

Evotec OAI AG and ActivBiotics Inc., a privately held biopharmaceutical company developing novel antibacterials, announced today that they have entered into a joint drug discovery project. Evotec OAI will apply its newly established rational drug design platform, EVOrationale(TM), to one of ActivBiotics' high profile anti-infective lead optimisation programmes.

Evotec OAI, through its integrated EVOrationale(TM) platform is well positioned to assist customers in delivering de novo structure determination, validation of screening hits and structure guided lead optimisation programmes. Over the past months, Evotec OAI has successfully applied the new platform to a range of targets including kinases, GPCRs, proteases, enzymes and more complex protein-ligand interactions.

Dr Michael Lutz, Senior VP of Marketing at Evotec OAI, said: "Since our recent launch of the EVOrationale(TM) platform, we see strong interest from the pharma and biotech industry to enhance their medicinal chemistry programmes through early integration of rational drug design approaches. We are delighted that ActivBiotics has chosen us as their partner to support their research efforts towards the discovery of novel antibiotics."

Dr Ronnie Farquhar, VP of Discovery and Pre-Clinical Development at ActivBiotics added: "We regard protein crystallography a valuable technology that should provide additional insights into the SAR of our novel antibacterial compounds. After evaluation of alternative partners, we believe that Evotec OAI is the best choice to assist our structural biology initiative."

https://www.bionity.com/en/news/38879/evotec-oai-to-apply-new-rational-drug-design-platform-to-high-priority-research-programme-from-activbiotics.html